Charles Hoyng is a partner in Latham & Watkins’ Boston and Silicon Valley offices and a member of the Life Sciences, Emerging Companies, and Intellectual Property and Technology Practice Groups. Dr. Hoyng's practice consists of negotiating and drafting life sciences technology license agreements and other similar agreements, and counseling in the development, protection, manufacture and distribution of products, particularly in the areas of:
After earning his Ph.D. and prior to earning his law degree, Dr. Hoyng was a post-doctoral research fellow at the California Institute of Technology, Pasadena, California, an Assistant Professor of Chemistry at Texas A&M University, and held several positions at Genentech, Inc., including Director, Organic Chemistry, and Project Director for Genentech's tissue plasminogen activator (t-PA) project.
In addition to the bar qualifications listed above, Dr. Hoyng is licensed to practice law in the Northern District of California and the Court of Appeals, Ninth Circuit. Dr. Hoyng is a member of the State Bar of California and the American Bar Association.
Dr. Hoyng is recognized:
As one of the leading life sciences attorneys in the world by Chambers USA (2008 through 2011)
In The International Who’s Who of Business Lawyers 2009 guide
As a "recommended lawyer" for licensing transactions by Intellectual Asset Management (IAM), 2012
As a "Life Sciences Star" for transactional work by LMG (Legal Media Group) Life Sciences, 2012
As a "Super Lawyer" in intellectual property by Super Lawyers, Thomson Reuters, 2004, 2005, 2012
Speaking Engagements and Publications
Dr. Hoyng has lectured frequently and is the author of several articles on topics related to his practice. Representative speaking engagements include:
- “Worldwide Company-University Collaborations," panelist at LESI 2012, Auckland, New Zealand, 2012
- "M&A/Dealmaking – Is M&A and Licensing Good for the Biotech Industry?" panel moderator, at Bio InvestorForum 2006, San Francisco, California, 2006
- "Pharmaceutical Co-Promotion and Co-Marketing Agreements in the US and Europe from a Biotech Perspective," panel moderator, at BayBio 2006: Accelerating Global Leadership, San Mateo, California, 2006
- “Intellectual Property and Licensing,” at the New Jersey Stem Cell Research Economic Summit, New Jersey Stem Cell Research Endowment Fund, Newark, New Jersey, 2004
- “Strategic Partnering and Licensing of Technology,” at International Biotechnology, M&A and Strategic Alliance, Tokyo, Japan, 2003
- “Strategic Partnering” at Merrill Lynch Asia Pacific Biotechnology Seminar, Roadmap for an Initial Public Offering, Singapore, 2003
- Practical Considerations in Licensing to and from Japanese Parties, The Journal of Proprietary Rights, Vol. 8, No. 6, June 1996
Dr. Hoyng has assisted public and private life sciences companies in structuring and negotiation of a wide variety of strategic alliance/joint venture transactions. Such transactions have concerned, for example, drug discovery and development, medical devices and diagnostics development and distribution, and technology access and product line extension matters.
Representative transactions include:
- Allergan, Inc.
- In its cross-border licensing and co-promote agreements with GlaxoSmithKline (GSK) to develop and promote Allergan’s BOTOX® in Japan and China, and to co-promote GSK’s IMITREX STATdose System® and AMERGE® in the US
- In its acquisition of Esprit to obtain the rights to market Sanctura XR, a once-daily treatment for overactive bladder
- Codexis, Inc.
- In a broad technology collaboration with Pfizer, Inc.
- In a research collaboration agreement with Royal Dutch Shell focusing on adapting enzymes to improve the conversion of a range of raw materials into high-performance fuels
- In a technology and development agreement with Dyadic International, Inc.
- GlobeImmune, Inc.
- In its $540 million oncology program collaboration with Celgene, Inc.
- In its license and collaboration agreement with Gilead for Hepatitis B
- OncoMed Pharmaceuticals, Inc. in its $1.4 billion collaboration with GlaxoSmithKline to develop and market antibody therapeutics for the treatment of cancer
- Plexxikon, Inc. in a $372 million multi-product collaboration with Wyeth Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- In its global alliance with Cell Genesys, Inc. for the development and commercialization of GVAX immunotherapy for prostate cancer
- In its collaboration agreement with Lexicon Genetics Incorporated in the area of hypertension
- In its collaboration agreement with XOMA
- In its acquisition of Syrrx Inc.